newsfilter
← Latest News
GlobeNewswire·

SkinHealth Systems Reports First Quarter 2026 Financial Results

SKIN
  • SkinHealth Systems Inc. reported Q1 2026 financial results for the period ended March 31, 2026, with total net sales of $64.9 million, a 6.7% decrease from $69.6 million in Q1 2025.
  • Delivery systems net sales declined to $18.5 million in Q1 2026 from $20.2 million in Q1 2025, while consumables net sales fell to $46.4 million from $49.4 million.
  • The company sold 746 delivery systems in Q1 2026 compared to 862 in the prior year period, though the active installed base grew to 36,419 units from 35,014 units.
  • GAAP net loss narrowed to $6.6 million in Q1 2026 from $10.1 million in Q1 2025, primarily driven by lower operational spend partially offset by reduced sales.
  • Adjusted EBITDA improved to $8.5 million in Q1 2026 from $7.3 million in Q1 2025, with an adjusted EBITDA margin of 13.1% compared to 10.4% the prior year.
  • Operating expenses decreased to $46.2 million in Q1 2026 from $60.6 million in Q1 2025 due to lower personnel-related expenses & reduced marketing spend.
  • The company revised its full-year 2026 net sales guidance down to a range of $280 million to $295 million, citing continued pressure on year-over-year device sales.
  • Revised Q2 2026 guidance projects net sales between $72 million to $77 million & adjusted EBITDA between $11 million to $13 million.
  • Regional sales analysis shows Americas remained the largest market with $44.6 million in net sales, while APAC & EMEA experienced declines in both device sales & consumables revenue.
  • The company announced a transition in Q2 2025 to a distributor partner for the China market, resulting in discontinued direct sales in that region.
  • Cash, cash equivalents, & restricted cash decreased to $204.4 million at March 31, 2026, from $232.7 million at December 31, 2025, reflecting a net cash used in operating activities of $5.6 million.
  • SkinHealth Systems will host a conference call on May 7, 2026, at 4:30 p.m. ET to review the first quarter 2026 financial results.